EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Cabotegravir—Global Access to Long-Acting Pre-exposure Prophylaxis for HIV

Toby Pepperrell, Samuel Cross, Andrew Hill

Open Forum Infectious Diseases · 04.01.2023 · 10 (1)

DOI: 10.1093/ofid/ofac673 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 15.12.2022. Verfasst von Toby Pepperrell und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, United Kingdom. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: International Treatment Preparedness Coalition.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A novel injectable pre-exposure prophylaxis, cabotegravir, has greater efficacy and acceptability than oral tenofovir/emtricitabine for prevention of HIV infection. Cabotegravir is currently priced at $22 200 per year, >185 times higher than the $60–$119 estimated cost-effectiveness threshold for middle-income countries (MICs). Following civil society pressure, ViiV provided access to generic versions in 90 countries with the Medicines Patent Pool (MPP), including all African nations. However, several MICs outside Africa have rapidly growing HIV epidemics. We analyzed the ViiV-MPP deal to assess population covered and gross domestic product (GDP) per capita. There were 38 countries excluded from the ViiV-MPP deal despite having a GDP per capita lower than the highest-earning African country. These countries include 2.4 billion people (30% global population), with an incidence of 122 000 (8%). For cabotegravir to have a significant impact on HIV infections, millions will need to be treated at affordable prices in a wide range of countries.

Schlagwörter

Stichwörter der Autor:innen

HIVPrEPaccesscabotegravir

Autor:innen und Institutionen

  • School of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, United Kingdom.
  • School of Medicine, Imperial College London, London, United Kingdom.
  • Department of Translational Medicine, Liverpool University, Liverpool, United Kingdom.

Förderung

  • International Treatment Preparedness Coalition

Zitieren

APA

Pepperrell, T., Cross, S., & Hill, A. (2023). Cabotegravir—Global Access to Long-Acting Pre-exposure Prophylaxis for HIV. Open Forum Infectious Diseases, 10(1). https://doi.org/10.1093/ofid/ofac673

Vancouver

Pepperrell T, Cross S, Hill A. Cabotegravir—Global Access to Long-Acting Pre-exposure Prophylaxis for HIV. Open Forum Infectious Diseases. 2023;10(1). doi:10.1093/ofid/ofac673

BibTeX
@article{Pepperrell2023,
  author = {Pepperrell, Toby and Cross, Samuel and Hill, Andrew},
  title = {Cabotegravir—Global Access to Long-Acting Pre-exposure Prophylaxis for HIV},
  journal = {Open Forum Infectious Diseases},
  year = {2023},
  volume = {10},
  number = {1},
  doi = {10.1093/ofid/ofac673}
}
Kostenlos starten →